First Eagle Investment Management LLC cut its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 52.9% in the third quarter, Holdings Channel.com reports. The firm owned 2,455,580 shares of the medical research company’s stock after selling 2,756,858 shares during the quarter. Bio-Rad Laboratories comprises approximately 1.4% of First Eagle Investment Management LLC’s investment portfolio, making the stock its 25th biggest position. First Eagle Investment Management LLC owned about 0.09% of Bio-Rad Laboratories worth $927,497,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its position in Bio-Rad Laboratories by 1.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,089,323 shares of the medical research company’s stock worth $303,637,000 after purchasing an additional 12,251 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Bio-Rad Laboratories by 57.8% during the second quarter. Assenagon Asset Management S.A. now owns 233,227 shares of the medical research company’s stock valued at $68,478,000 after buying an additional 85,393 shares during the period. Hound Partners LLC boosted its position in shares of Bio-Rad Laboratories by 125.9% during the first quarter. Hound Partners LLC now owns 97,724 shares of the medical research company’s stock valued at $27,241,000 after buying an additional 54,456 shares during the period. Hosking Partners LLP boosted its position in shares of Bio-Rad Laboratories by 1.1% during the third quarter. Hosking Partners LLP now owns 95,472 shares of the medical research company’s stock valued at $36,061,000 after buying an additional 1,042 shares during the period. Finally, Wellington Management Group LLP bought a new position in shares of Bio-Rad Laboratories during the second quarter valued at approximately $17,690,000. 65.24% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on BIO shares. Citigroup increased their price target on Bio-Rad Laboratories from $300.00 to $330.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Weiss Ratings raised Bio-Rad Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, November 9th. Royal Bank Of Canada boosted their price objective on Bio-Rad Laboratories from $390.00 to $440.00 and gave the company an “outperform” rating in a report on Thursday, November 5th. Wells Fargo & Company boosted their price objective on Bio-Rad Laboratories from $310.00 to $330.00 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. Finally, Zacks Research raised Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Bio-Rad Laboratories presently has an average rating of “Hold” and an average price target of $366.67.
Insider Transactions at Bio-Rad Laboratories
In other news, EVP Courtney C. Enloe sold 902 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $386.17, for a total transaction of $348,325.34. Following the transaction, the executive vice president directly owned 750 shares of the company’s stock, valued at approximately $289,627.50. This trade represents a 54.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP James Barry sold 1,400 shares of Bio-Rad Laboratories stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $385.63, for a total transaction of $539,882.00. Following the sale, the executive vice president directly owned 625 shares of the company’s stock, valued at $241,018.75. This represents a 69.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 3,221 shares of company stock valued at $1,247,049. 30.34% of the stock is currently owned by company insiders.
Bio-Rad Laboratories Trading Down 0.4%
BIO stock opened at $358.91 on Wednesday. The company has a market capitalization of $9.65 billion, a PE ratio of 9.45 and a beta of 1.06. Bio-Rad Laboratories, Inc. has a 12 month low of $236.73 and a 12 month high of $396.23. The firm’s 50-day moving average is $372.07 and its 200 day moving average is $318.08. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.18 and a quick ratio of 2.37.
Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The medical research company reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.23 by $0.42. The company had revenue of $656.40 million during the quarter, compared to analyst estimates of $649.94 million. Bio-Rad Laboratories had a net margin of 39.45% and a return on equity of 3.58%. The firm’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter last year, the business posted $2.26 EPS. On average, research analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.71 EPS for the current year.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products used in life science research and clinical diagnostics. Founded in 1952 by David and Alice Schwartz, the company is headquartered in Hercules, California, and serves customers around the world. Through its Life Science segment, Bio-Rad supplies instruments, reagents, and software for areas including cell biology, genomics, protein analysis, and drug discovery. Its products support research at academic institutions, biotechnology and pharmaceutical companies, and other laboratories.
See Also
- Five stocks we like better than Bio-Rad Laboratories
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
